期刊文献+

人膝骨关节炎滑膜血管活性肠肽的表达及其与疼痛的关系 被引量:5

THE EXPRESSION OF VASOACTIVE INTESTINAL PEPTIDE IN HUMAN KNEE OSTEOART-HRITIS SYNOVIUM AND THE relationship BETWEEN VASOACTIVE INTESTINAL PEP-TIDE AND KNEE OSTEOARTHRITIS PAIN
下载PDF
导出
摘要 目的:研究血管活性肠肽(vasoactive intestinal peptide,VIP)在人膝骨关节炎滑膜中的表达特点,并探讨其与患者膝关节疼痛程度之间的相关性。方法:采集18例骨关节炎患者膝关节滑膜,根据术前视觉模拟疼痛评分(visual analogue scale,VAS)分为轻中度疼痛组(M组)和重度疼痛组(S组),7例外伤病人滑膜作为对照组(C组)。检测患者和正常人滑膜内VIP的含量和位置。结果:正常膝关节和骨关节炎膝关节滑膜均表达VIP,滑膜衬里层和衬里下层的表达无显著性差异(P>0.05)。轻中度疼痛组(M组)滑膜VIP表达高于对照组(C组)和重度疼痛组(S组)(P<0.05)。VIP与疼痛无线性相关。结论:VIP可能在人膝骨关节炎中参与轻度致痛作用,而在重度疼痛中不起主要作用。 Objective: To detect the vasoactive intestinal peptide (VIP) expression in ht, man knee osteoarth- ritis synovium and the relationship between VIP and knee osteoarthritic pain. Methods: Osteoarthritic knee synovium tissues from 18 patients were collected. According to visual analogue scale (VAS), the synovium tissues were divided into two groups: mild to moderate pain group (M group) and severe pain group (S group). Normal knee synoviurn tissues l^om 7 patients with trauma were collected as control (C group). The VIP expression and location were observed. Results: VIP was expressed in both normal and osteoarthritis knee joint synovium, and there are no difference in VIP expression between synovial lining and sublining layer (P 〉 0.05). The VIP expressed in mild to moderate pain group (M group) was higher than that in the control group (C group) and severe pain group (S group) (P 〈 0.05). VIP expression in synovial has no linear correlation with pain scores. Conclusion: VIP involves in mild to moderate pain in human knee osteoarthritis, but may not play a major role in the severe pain.
出处 《中国疼痛医学杂志》 CAS CSCD 北大核心 2012年第7期413-417,共5页 Chinese Journal of Pain Medicine
基金 湖南省发展与改革委员会项目资助[2007]896
关键词 血管活性肠肽 骨关节炎 滑膜 疼痛 Vasoactive intestinal peptide Osteoarthritis Synovium Pain
  • 相关文献

参考文献14

  • 1Zaka R, Stokes D, Dion AS, et al. P5L mutation in Ank results in an increase in extracellular inorg- anic pyrophosphate during proliferation and nonm- ineralizing hypertrophy in stably transduced ATD C5 cells. Arthritis Res Ther, 2006, 8 : R164.
  • 2McDougall J J, Watkins L, Li Z, et al. Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain, 2006, 123 : 98- 105.
  • 3Pulsatelli L, Pulsatelli L, Dolzani P, et al. Synovial expression of vasoactive intestinal peptide in poly- myalgia rheumatica. Clin Exp Rheumatol, 2006, 24 : 562 - 566.
  • 4陈霞光,雷光华,钱锐,肖诗梁,蔡幸健,刘振逾.血管活性肠肽在关节炎关节软骨中的表达及临床意义[J].赣南医学院学报,2011,31(1):26-28. 被引量:1
  • 5郑伟,汪宝军,叶立民.灰度值、光学密度值与免疫组化片阳性表达强弱的关系[J].临床与实验病理学杂志,2003,19(5):566-567. 被引量:43
  • 6Wyke B. The neurology of joints: a review of gene- ral principles. Ann R Coll Surg Engl, 1967, 41 : 25 50.
  • 7WallPD,MelzackR著.赵宝昌,崔秀云,主译.疼痛学.第三版.沈阳:辽宁教育出版社,2000:150.
  • 8Christensen SB. Osteoarthritis changes of bone, cartilage and synovial membrane in relation to bone scintigraphy. Acta Orthop Scand suppl, 1985, 56 : 214 - 243.
  • 9Kallakuri S, Singh A, Chert C, et al. Demonstrati- on of substance P, calcitonin gene-related peptide, and protein gene product 9.5 containing nerve fibers in human cervical facet joint capsules. Spine, 2004, 29 : 1182 - 1186.
  • 10Oku R, Satoh M, Fujii N, et al. Calcitonin gene- related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res, 1987, 403 : 350 - 354.

二级参考文献23

  • 1陈峰,毕英佐,曹永长,何洁.血管活性肠肽在禽类上的研究进展[J].中国家禽,1997,19(1):31-33. 被引量:15
  • 2Said S,Mutt V.Polypeptide with broad biologlcal activity:isolationfrom small intestine[J].Science,1970,169(951):1217-1218.
  • 3Sutton S.The contribution of the synovium,synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis[J].Vet J,2007,20(4):1687-11689.
  • 4Juarranz Y.Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis[J].Arthritis Res Ther,2005,7(5):1034-1045.
  • 5Delgado M,E Gonzalez-Rey,D Ganea.VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells[J].FASEB J,2004,18(12):1453-1457.
  • 6Gutierrez-Canas I.VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts[J].Rheumatology (Oxford),2006,45(5):527-532.
  • 7McDougall J,L Watkins,Z Li.Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis[J].Pain,2006,123(1-2):98-105.
  • 8Schuelert N,J McDougall.Electrophysiological evidence that the vasoactive intestinal peptide receptor antagonist VIP6-28 reduces nociception in an animal model of osteoarthritis[J].Osteoarthritis Cartilage,2006,14(11):1155-1162.
  • 9Outerbridge RE,Dunlop JAY.The problem of chondromalaonia patella[J].Clin Orthop,1975,110:177-196.
  • 10Mankin H,Dorfman H,Lippiello L,et al.Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips[J].J Bone Joint Surg (Am),1971,53:523-537.

共引文献44

同被引文献80

  • 1王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4):1-8. 被引量:2039
  • 2陈朝蔚,陈永强.骨关节炎血管生成与炎症的关系[J].国际骨科学杂志,2007,28(1):33-35. 被引量:5
  • 3赵欣,于布为.疼痛机制研究进展[J].上海医学,2007,30(6):462-465. 被引量:69
  • 4王琦,朱燕波,吴承玉,邓棋卫,沈世林,崔正植,夏仲元,折笠秀树.中医体质与健康相关生命质量的相关性[J].中国组织工程研究与临床康复,2007,11(49):9946-9950. 被引量:49
  • 5Neogi T,Zhang Y.Epidemiology of osteoarthritis.Rheum Dis Clin North Am,2013,39(1):1-19.
  • 6Kon E,Filardo G,Drobnic M,et al.Non-surgical management of early knee osteoarthritis.Knee Surg Sports Traumatol Arthrosc,2012,20(3):436-449.
  • 7Shah S,Mehta V.Controversies and advances in nonsteroidal anti-inflammatory drug(NSAID)analgesia in chronic pain management.Postgrad Med J,2012,88(1036):73-78.
  • 8Varadi G,Zhu Z,Blattler T,et al.Randomized clinical trial evaluating transdermal Ibuprofen for moderate to severe knee osteoarthritis.Pain Physician,2013,16(6):E749-762.
  • 9Conaghan PG,Dickson J,Bolten W,et al.A multicentre,randomized,placebo-and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Trans-fersome gel(IDEA-033)with ketoprofen-free vehicle(TDT 064)and oral celecoxib for knee pain associated with osteoarthritis.Rheumatology(Oxford),2013,52(7):1303-1312.
  • 10Komatsu T,Sakurada T.Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe.Eur J Pharm Sci,2012,47(5):890-895.

引证文献5

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部